FDA Approves New Drug for Advanced Head and Neck Squamous Cell Carcinoma

Rybrevant Faspro is the first approval in 10 years for recurrent, metastatic disease after platinum-based chemotherapy and immunotherapy
throat neck
Adobe Stock
Published on: 
Updated on: 
Loading content, please wait...